SURECAN Trial

  • Research type

    Research Study

  • Full title

    SUrvivors' Rehabilitation Evaluation after CANcer trial: A multi-centre, pragmatic, randomised controlled trial of comparing enhanced Acceptance and Commitment Therapy (plus) added to usual aftercare, versus usual aftercare only

  • IRAS ID

    260823

  • Contact name

    Stephanie Taylor

  • Contact email

    s.j.c.taylor@qmul.ac.uk

  • Sponsor organisation

    Barts Health NHS Trust

  • ISRCTN Number

    ISRCTN67900293

  • Duration of Study in the UK

    3 years, 5 months, 30 days

  • Research summary

    Some two million people in the UK are living with or beyond cancer -“cancer survivors”. About a third of these patients report poor quality of life (QoL), or well-being, due to problems such as fatigue, fear of cancer recurrence, and concerns about returning to work.

    From talking to patients we have found that important aspects of QoL include physical abilities and psychological well-being. We surveyed cancer services to see what aftercare is provided and found it did not address important issues highlighted by patients. We therefore are in need of better aftercare for “cancer survivors”.

    Since the best approaches are only moderately effective, we decided to adopt Acceptance and Commitment Therapy (ACT), as we thought this would provide better aftercare. ACT puts patients’ views about what they value most in their lives at the heart of the therapy, in order to improve their quality of life. ACT helps patients to accept what they cannot change (e.g. the cancer might recur) and commit themselves to goals they are able and want to achieve, based on their own values (e.g. becoming closer to loved ones). We know that exercise is helpful and return to work/vocational activity is important to many patients, therefore will integrate ACT with options for physical activity and work support, if these are deemed important by the patient (thus: ACT+ or enhanced ACT).

    This study will consist of a pilot RCT with the aim to recruit and retain, with follow-up data, sufficient number of patients for a clinical trial. Depending on meeting progression criteria, the pilot RCT will seamlessly progress into a definitive RCT comparing ACT+ and usual aftercare, with usual aftercare only, answering if ACT+ with usual aftercare is more effective and cost-effective in improving the QoL of participants living with and beyond cancer than usual aftercare only.

  • REC name

    South West - Cornwall & Plymouth Research Ethics Committee

  • REC reference

    19/SW/0214

  • Date of REC Opinion

    20 Jan 2020

  • REC opinion

    Further Information Favourable Opinion